Discover
RIGL
Rigel Pharmaceuticals, Inc.
38.29
1 x 33.11
1 x 44.51
bid
ask
-
0.83
2.12%
1 @ 04:00 PM
38.00 -0.29 (0.76%)
| Ytd | -10.60% | |
| 1y | 104.65% |
38.24
day range
39.57
18.24
52 week range
52.24
| Open | 38.85 | Prev Close | 39.12 | Low | 38.24 | High | 39.57 | Mkt Cap | 708.44M |
| Vol | 240.84K | Avg Vol | 390.65K | EPS | 19.29 | P/E | 1.98 | Forward P/E | 19.49 |
| Beta | 0.95 | Short Ratio | 1.69 | Inst. Own | 68.01% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 31.20 | 200-d Avg | 34.01 | 1yr Est | 31.33 |
| Income Statement | |||
| Total Revenue | 58.82M | ||
| Revenues (USD) | 58.82M | ||
| Cost of Revenue | 4.61M | ||
| Gross Profit | 54.21M | ||
| Operating Expenses | 42.33M | ||
| Research and Development Expense | 11.68M | ||
| Selling, General and Administrative Expense | 30.65M | ||
| Operating Income | 11.89M | ||
| Interest Expense | 1.43M | ||
| Income Tax Expense | 3.00M | ||
| Net Income | 8.65M | ||
| Net Income Common Stock | 8.65M | ||
| Net Income Common Stock (USD) | 8.65M | ||
| Consolidated Income | 8.65M | ||
| Earnings per Basic Share | 0.47 | ||
| Earnings per Basic Share (USD) | 0.47 | ||
| Earnings per Diluted Share | 0.44 | ||
| Earning Before Interest & Taxes (EBIT) | 13.09M | ||
| Earning Before Interest & Taxes (USD) | 13.09M | ||
| Weighted Average Shares | 18.41M | ||
| Weighted Average Shares Diluted | 19.69M | ||
| Balance Sheet | |||
| Cash and Equivalents | 24.41M | ||
| Cash and Equivalents (USD) | 24.41M | ||
| Investments | 122.27M | ||
| Investments Current | 122.27M | ||
| Trade and Non-Trade Receivables | 49.95M | ||
| Current Assets | 234.03M | ||
| Property, Plant & Equipment Net | 785.00K | ||
| Total Assets | 504.61M | ||
| Debt Current | 30.50M | ||
| Total Debt | 45.72M | ||
| Current Liabilities | 89.49M | ||
| Debt Non-Current | 15.22M | ||
| Total Liabilities | 104.71M | ||
| Accumulated Retained Earnings (Deficit) | -1.01B | ||
| Accumulated Other Comprehensive Income | -128.00K | ||
| Shareholders Equity | 399.90M | ||
| Shareholders Equity (USD) | 399.90M | ||
| Assets Non-Current | 270.58M | ||
| Total Debt (USD) | 45.72M | ||
| Deferred Revenue | 28.08M | ||
| Goodwill and Intangible Assets | 24.16M | ||
| Inventory | 11.65M | ||
| Liabilities Non-Current | 15.22M | ||
| Trade and Non-Trade Payables | 4.49M | ||
| Tax Assets | 243.28M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 597.00K | ||
| Net Cash Flow from Financing | -10.92M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -16.17M | ||
| Issuance (Purchase) of Equity Shares | -3.42M | ||
| Issuance (Repayment) of Debt Securities | -7.50M | ||
| Net Cash Flow from Investing | -7.97M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -7.97M | ||
| Net Cash Flow from Operations | 2.73M | ||
| Share Based Compensation | 3.46M | ||